Total knee replacement with and without emicizumab: a unique comparison of perioperative management

Blood Adv. 2020 Mar 10;4(5):855-857. doi: 10.1182/bloodadvances.2019001060.


  1. Prophylaxis with emicizumab was used in a patient with severe hemophilia with an inhibitor who underwent knee surgery.

  2. Use of emicizumab during surgery led to less recombinant factor VIIa and less bleeding, in addition to cost savings, for this patient.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment